meningococcal group b vaccine

The MenB vaccine guards against a specific strain of meningococcal bacteria, known as type B. While it is not currently part of routine vaccinations for healthy individuals, it is recommended for children and teenagers at higher risk for meningococcal disease, starting at age 10.

People who have certain conditions that weaken their immune system, including teens who are HIV positive, should receive meningococcal vaccine starting from the age of 2 months. Additionally, they should receive booster shots every three to five years, depending on their age.

Messina advises parents to give their teens both meningitis vaccines, even though the meningitis B vaccine is optional on the CDC schedule. According to Messina, this vaccine is crucial because meningitis is a highly fatal disease and there is very little time to intervene once a child becomes ill.

In the United States, there are three types of meningococcal vaccines available: Meningococcal conjugate (MenACWY) vaccines, including Menveo® and MenQuadfi®, and Serogroup B meningococcal (MenB) vaccines, including Bexsero® and Trumenba®.

To provide immunization, you can choose between two options: Bexsero, which requires two doses given four weeks apart, or Trumenba, which requires two doses given six months apart. If the second dose of Trumenba is given before the six-month mark, a third dose should be given at least four months after the second dose.

In the UK, it is advised that infants be given the MenB vaccine at 8 weeks, 16 weeks, and one year old. This vaccine does not contain live bacteria and therefore cannot result in meningococcal disease.

The first vaccine for serogroup B meningococcal disease, rLP2086 (Trumenba®, Pfizer), received its license for use in individuals aged 10-25 on October 29, 2014. Subsequently, on January 23, 2015, 4CMenB was approved for use in the same age group.

The Meningococcal B vaccine is provided at no cost through the National Immunisation Program for Aboriginal and Torres Strait Islander children who are 2 months, 4 months, 6 months (with eligible medical conditions), and 12 months old.

To ensure maximum protection during the period when adolescents are most vulnerable, it is recommended by the CDC to administer MenB vaccines between the ages of 16 and 18. Vaccine providers are advised to give the MenB vaccine series during later adolescence, with the preferred age range being 16 through 18 years.

The CDC advises that all preteens and teens should receive the meningococcal vaccination. Specifically, 11 to 12 year olds should get a single dose of the meningococcal conjugate (MenACWY) vaccine. Additionally, a booster dose is recommended at age 16 to ensure continued protection.

The MenB vaccine is included in the NHS vaccination schedule and is administered to babies at 8 weeks and 16 weeks.

For healthy adolescents who are not at increased risk for serogroup B meningococcal disease, give them 2 doses. The second dose should be given 6 months after the first dose. However, for individuals who are 10 years of age or older and are at increased risk for meningococcal disease, administer 3 doses.

If you are concerned about meningococcal disease, it is advisable to consult with a healthcare provider regarding vaccination. The Australian Immunisation Handbook suggests that certain groups, such as infants, children, adolescents, and young adults, should consider receiving the meningococcal vaccine.

MPSV4 and MCV4 are effective in preventing four types of meningococcal disease, accounting for approximately 70% of cases in the United States. MenB vaccines are specifically designed to prevent the Meningococcal B strain. MCV4 is the preferred option for individuals under the age of 55. For teenagers, it is recommended to receive one dose at the age of 11-12 and a booster dose at the age of 16.

Teens and young adults aged 16 to 23 are eligible to receive the MenB vaccine. If they are receiving both the MenACWY and MenB vaccines during the same visit, they have the option to receive the MenABCWY vaccine instead. Additionally, the CDC advises meningococcal vaccination for other individuals, including children and adults, who are at a higher risk for meningococcal disease.

The meningococcal vaccine is recommended for the following high-risk groups:
– All infants and young children, especially those under 2 years old.
– Adolescents aged 15 to 19 years.
– Individuals who have close household contact with someone who has meningococcal disease and have not been immunized.

The Men B vaccine series can be given to individuals aged 16 to 23 to offer temporary protection against most strains of serogroup B meningococcal disease. It is recommended to administer the Men B vaccine between the ages of 16 and 18.

Meningococcal bacteria can be transmitted from person to person through the sharing of respiratory and throat secretions, such as saliva or spit. However, close contact, such as coughing or kissing, or prolonged exposure is usually required for transmission. It is important to note that these bacteria are not as easily contagious as the germs responsible for the common cold or the flu.

Meningococcal disease caused by meningococcal B bacteria is most prevalent in children under the age of 5, especially infants under 1 year old. Additionally, late adolescence and early adulthood are also high-risk age groups. In recent years, there has been a significant increase in cases of meningococcal W in Australia.

The MenB vaccine is designed to safeguard your baby from contracting meningococcal group B bacteria, which are responsible for approximately 90% of meningococcal infections in young children. These infections can have severe consequences, such as meningitis and sepsis.

Based on information from the CDC, individuals who have experienced a life-threatening reaction to a previous meningitis vaccination dose or have a severe allergy to any ingredient in the vaccine should not receive the vaccination or should wait until their doctor deems it safe for them to do so.

Meningococcal disease can affect anyone, but college freshmen living in dorms are at higher risk and should receive the vaccination.

The CDC advises that all preteens and teenagers receive meningococcal vaccines. Additionally, in specific circumstances, the CDC suggests that other children and adults should also receive meningococcal vaccines.

The CDC advises that individuals who are 10 years or older and have an elevated risk for meningococcal disease should receive routine MenB vaccination.

Meningococcal disease, a bacterial infection that leads to bloodstream infections and meningitis, is more likely to affect college students, particularly those residing in dormitories, due to their close proximity to one another.

It is not recommended to administer MenB vaccines to individuals under the age of 10. If a person has experienced an allergic reaction after a previous dose of MenB vaccine or has severe, life-threatening allergies, they should consult with their healthcare provider before receiving a MenB vaccine.

Despite the higher prevalence of MenB among individuals aged 16-23 and the significantly increased risk for college students, the requirement for Meningitis B vaccination remains low among colleges. In the United States, there are over 5,300 colleges and universities, as well as more than 30,000 high schools. However, only a limited number of 40+ schools are currently mandating the Meningitis B vaccine.

There are two meningitis vaccines that provide protection against four types of meningococcal disease. There is also a separate vaccine that specifically targets serotype B, which is another cause of meningitis.

State MenACWY vaccine requirements for college/university vary by state. In California, all new college or university students residing in student housing are required to have the vaccine. In Colorado, the requirement also applies to all incoming students. In Connecticut, the vaccine is required for all incoming students residing on campus. Similarly, in Delaware, all incoming students are required to have the vaccine.